Pharmaceutical industry – Page 39
-
Business
Amgen to axe 300 Onyx employees
Amgen will close its Onyx facility in South San Francisco in December
-
Business
Mergers and moves trigger pharma layoffs
Shire expects to sack 500 or more employees, while Merck and GSK also wield the axe
-
Business
US approves biosimilar filgrastim
Sandoz’s version of Amgen’s Neupogen is ‘biosimilar’ but not ‘interchangeable’
-
BusinessAbbVie to buy Pharmacyclics for pipeline boost
$21bn deal gives AbbVie a share in sales of blockbuster cancer drug as its own biggest sellers face patent expiry
-
Business
Mallinckrodt to buy Ikaria to expand in US hospitals
$2.3bn deal brings nitric oxide ventilator system for newborns with respiratory failure
-
Business
J&J to sell cardiac devices to wholesaler Cardinal
Commodity technology no longer fits with company’s focus on growth and innovation
-
Business
AstraZeneca to spin off anti-infectives research
Early-stage research will transfer to a new company, while AZ and MedImmune retain late-stage programmes
-
BusinessUS opens up home DNA screening
FDA approves single disease genetic test and clears pathway for similar devices
-
Business
BMS bolsters immuno-oncology with pair of deals
Firm will acquire Flexus Biosciences and collaborate with Rigel
-
Business
Europe approves stem cell therapy
Treatment for burn-damaged eyes uses patient’s own scaffold-grown cells
-
Business
Valeant to buy Salix for $14.5bn
Companies expect $500m in savings through ‘R&D rationalisation’
-
OpinionTantalising technology
Computer-assisted drug design always looks like it’s just about to work, says Derek Lowe, but the reality is complicated
-
Business
Teva wins generic esomeprazole race
US approval of heartburn drug after Ranbaxy version was withdrawn by regulators
-
Business
US approves internal tissue glue
Urethane-based TissuGlu aids healing after abdominal surgery
-
Business
Hospira buyout is a shot in the arm for Pfizer’s biosimilars
$17bn deal, intended to bolster sterile injectable and biologics capabilities, will be financed with existing cash and new debt
-
Business
EU regulator calls for generic drug suspensions
The EMA wants hundreds of formulations off the market after identifying systematic fraud in a major Indian contract clinical research organisation
-
BusinessRoche chases bolt-on acquisitions as it pushes into genomics
Company’s recent shopping spree aims to harness genome sequencing to advance personalised treatments
-
Business
Shire deepens rare disease focus with NPS buyout
Approval of parathyroid hormone drug further validates acquisition decision
-
Business
Ansun settles fraud case for $2m
Executives fiddled timesheets to overcharge US funding agency on grants and research contracts
-
Business
Biogen Idec to buy Convergence for pain pipeline
UK firm will remain intact as a ‘centre of excellence’ in pain R&D for Biogen